Therefore, we selected the gene expression profile and clinical features from the immunotherapy cohort (imvigor210) of urothelial carcinoma (UC) treated with anti-PD-L1 drugs to study the relationship between the constructed risk signature and immune response. Here, CD274 is linked to urothelial carcinoma.